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Essential hypertension is a disease involving impaired endothelium-dependant 
vasomotor function which is partially mediated through an increase in reactive oxygen 
species. Recent evidence has demonstrated that resveratrol (RSV), a polyphenol with 
antioxidant capabilities, alleviates this impaired endothelium-dependant vasomotor function 
and can provide cardiovascular health benefits. The aim of this study was to examine the 
effects of chronic resveratrol treatment for 28 days on the endothelium-dependant vasomotor 
function and hemodynamic measures of the common carotid artery (CCA) of Spontaneously 
Hypertensive rat (SHR) aged 20-22 weeks at a high (2.7 mg per day, equivalent to a 500mg 
dose in humans) and a low (0.027mg per day, equivalent to moderate red wine consumption 
in humans) dose. The 20-22 week old SHR (n=9) demonstrated an elevated mean arterial 
blood pressure compared to the normotensive control, Wistar Kyoto rats (WKY) (n=9) 
(p<0.001). The SHR also demonstrated decreased endothelium-dependant vasorelaxation and 
increased endothelium-dependant contraction, indicating impaired endothelium-dependant 
vasomotor function. Following chronic treatment with resveratrol for 28 days at a high dose 
maximal relaxation to acetylcholine (ACh) of phenylephrine (PE) pre-contracted CCA vessels 
was increased when compared to SHR CON (High 100.4 + 5.2%, CON 53.6 + 6%) 
(p<0.001). This difference is possibly mediated by improved nitric oxide (NO) bioavailability. 
This study also confirmed that SHR demonstrate increased endothelium-dependant 
contractions in quiescent, non pre-contracted rings of the CCA (P<0.001). High dose 
resveratrol treatment reduced SHR endothelium-dependant contraction in the CCA compared 
to SHR CON (High 55 + 5.4%, CON 68 + 5%) (p<0.05). This effect was likely mediated by 




(p<0.05). This result is likely to be cause by inhibition of cycloxygenase 1 (COX 1) since 
reversal of SHR endothelium-dependant contraction is demonstrated following inhibition of 
COX 1, an interpretation supported by the observation that resveratrol treatment had no effect 
on the sensitivity of the thromboxane-prostaglandin receptor, and no effect on the protein 
expression of COX 1. This study indicates that chronic treatment with resveratrol at a high 
dose improves CCA endothelium- dependent vasomotor function in SHR via improved NO 
bioavailability and a reduction in endothelium-dependant PGI2-mediated contraction. These 
improvements in vasomotor function produced an alteration in vascular tone to a less 
contracted state. If these observations extend to the resistance vasculature they could 
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Resveratrol is a chemical compound with numerous cardiovascular health benefits. 
Previous studies conducted by this laboratory have indicated that resveratrol may alleviate 
vasomotor dysfunction often associated with hypertension. This study will examine the 
effects of chronic dietary resveratrol treatment on aspects of endothelial dysfunction not 
previously examined; namely its effect on endothelium-dependant contractions. A brief 
introduction to hypertension and its prevalence in society will be outlined with a focus on 
hypertension’s association with endothelial dysfunction. Two key regulators of endothelial 
dysfunction, nitric oxide (NO) and prostacyclin (PGI2) will be introduced and the changes 
occurring to these chemicals during the progression of endothelial dysfunction will be 
characterized. The cardiovascular effects of resveratrol will be introduced in more detail, 
outlining the rationale for the positive effects seen in previous studies and identifying the 
novel effects that will be illuminated in the present study.  This will be followed by the 
experimental methods used to examine changes in the vascular function of both 
Spontaneously Hypertensive Rats (SHR) and Wistar Kyoto Rats (WKY), the animal models 
used in this study. The methods will be followed by the results of the study, and finally the 
main findings of the study will be discussed and who they relate to the original hypothesis. 
Introduction: 
Hypertension is defined as chronically elevated blood pressure consisting of a systolic 
pressure in excess of 140 mmHg and a diastolic pressure in excess of 90 mmHg (1,2). This 
disorder is associated with a multitude of diseases including coronary artery disease, obesity 
and diabetes, all of which have an increasing prevalence in Canadian society.  One in every 





increase in the coming years (3). For this reason, it is important to develop an understanding 
of the pathophysiological changes in the heart and blood vessels associated with hypertension.     
The endothelium, a single layer of endothelial cells located on the luminal side of the 
blood vessel wall, plays an important role in control of vascular tone, which can be altered in 
hypertension. Under normal conditions, the endothelium can be stimulated by a large number 
of physical and biological factors to elicit either dilation or constriction of blood vessels. 
However, in diseased states, the endothelial control of vascular tone becomes compromised, 
resulting  in endothelial dysfunction (2,4,5). This dysfunction is known to result from a 
number of contributing factors including; vascular injury, altered molecular signaling and an 
increase in reactive oxygen species (6-8).These factors result in impaired endothelium-
mediated dilation and an increase in endothelium-dependant contractions, which are 
hallmarks of endothelial dysfunction (9-12). Endothelial dysfunction is often correlated with 
an increase in blood pressure seen in hypertensive patients (13).  To fully understand the 
effects of endothelial dysfunction on vascular control, it is first necessary to comprehend the 
normal cellular mechanisms which become dysfunctional with hypertension.  
Endothelial Cell Control of Vascular Tone: 
It was initially thought that the layer of endothelial cells located on the luminal side of 
the blood vessel wall did not play a role in the control of vascular tone. However, this idea 
was changed in 1980 with the important discovery of an endothelial derived relaxation factor 
(EDRF) by Furchgott and Zawadzki, now known as nitric oxide (14).  This discovery resulted 
in a change in the focus of vascular research to illuminate the role of the endothelium in the 





It has since been shown that a number of vaso-active substances or stimuli known to 
elicit a response from the vascular smooth muscle (VSM) are produced and released by the 
endothelium (15). In response to a stimulus, the endothelium can release two main classes of 
metabolites, which affect the tonic state of VSM: endothelial derived relaxing factors, and 
endothelial derived contraction factors (EDCF) (16,17). The balance between EDRFs and 
EDCFs is a determinant of the basal tone of an artery.  Two of the most notable EDRFs, NO 
and PGI2, play an important role in the control of vascular tone in a normotensive state, and 
are main foci of endothelial dysfunction research (4). NO, normally an important signaling 
molecule responsible for producing dilation, decreases in bioavailability during the 
progression of endothelial dysfunction. The reduction in NO bioavailability is apparent in 
hypertensive patients who suffer from impaired NO mediated dilation (18). This result has 
also been reproduced in isolated sections of the common carotid artery (CCA) and thoracic 
aorta of hypertensive animal models (4). PGI2, an EDRF, is normally involved in the control 
of vascular tone predominantly producing relaxation of the blood vessel. However during 
endothelial dysfunction, there are multiple alterations in the PGI2 signaling pathway, the end 
result being a transition in the functional role of this molecule from an EDRF to an EDCF (1). 
To understand the functional alterations occurring to these EDRFs it is important to outline 
the normal function of NO and PGI2 and the underlying mechanisms causing these alterations.       
Nitric Oxide: 
NO is a gaseous transmitter with a very short half life (19). It is produced from L-
arginine by endothelial nitric oxide synthase (eNOS) in response to an increase in intracellular 
calcium (20,21). Once NO is released by the endothelium, it permeates the cell membrane of 





which increases cyclic guanosine monophosphate (cGMP).  cGMP then causes relaxation of 
the VSM through a number of pathways in the VSM (1). The basic mechanism of NO 
synthesis and function on the VSM, as well as the determinants of NO bioavailability, are 
illustrated in figure 1. (2)  
NO has been shown to have a role in the maintenance of blood pressure. When Sainz 
and colleagues chronically treated rats with the NOS inhibitor L-NG-Nitroarginine methyl 
ester (L-NMMA), a significant increase in blood pressure resulted. Similarly eNOS knock-out 
models also display an increase in blood pressure (22). As mentioned previously, patients 
with essential hypertension exhibit impaired NO mediated dilation, indicating hypertensive 
patients suffer from dysfunctional NO signaling (18). Though this impaired NO mediated 
dilation has also been documented in animal models of essential hypertension, such as the 
spontaneously hypertensive rats (SHR). The SHR have demonstrated an increase in eNOS 
expression and phosphorylation in both the CCA and thoracic aorta (12). This finding 
indicates that the impaired NO signaling in hypertension is not necessarily due to a lack of 
NO production. 
NO bioavailability has been shown to be heavily influenced by the state of oxidative 
stress of the cell. In models with increased oxidative stress, such as the SHR, there is an 
associated decrease in NO bioavailability. This decrease is mediated in part through reactive 
oxygen species such as the superoxide anion (4,5,23). NO is a highly unstable molecule 
which, when exposed to superoxide, reacts readily to form peroxynitrite and loses its ability to 
cause VSM relaxation, as seen in figure 1. Support for superoxide’s role in the reduction of 
NO bioavailability has come from multiple sources in the literature. A number of 





its ability to act on the VSM. These include; treatment with exogenous superoxide, inhibition 
of superoxide dismutase (SOD), treatment with exogenous SOD and SOD mimetics, and 
inhibition of superoxide production through inhibition of NADPH oxidase (24-26). These 
findings support the theory that reactive oxygen species is a major determinant of decreases in 
bioavailability of NO leading to impaired signaling, a hallmark of endothelial dysfunction in 
hypertension. 
Prostacyclin: 
PGI2 is an EDRF that can play a significant role in the development of endothelial 
dysfunction. In a normotensive state, the production of PGI2 begins with the stimulation of 
receptors on the endothelial cell membrane. Through a G protein coupled mechanism, 
phospholipase A2 (PLA2) is activated, which mobilizes arachidonic acid, a fatty acid found 
within the cell membrane (27). Phospholipase A2s are members of a super family of 
intracellular and secreted enzymes which is responsible for the deacylation of arachidonic 
acid from glycerol. The phospholipase A2 super family is split into categories based on 
structure, intracellular location, and regulation properties (28). The most abundant and well 
characterized category is the cytosolic phospholipase A2, This category contains both 
calcium-independent and calcium-dependant isoforms (28). It is the calcium dependant 
isomer of cytosolic phospholipase A2 that is thought to be stimulated as a part of the PGI2 
signaling pathway. However some recent studies by Vanhoutte et al. indicate that both 
calcium-dependant and calcium-independent isoforms of phospholipase A2 could be 
contributing to the mobilization of arachidonic acid in the PGI2 pathway (29). Once 
arachidonic acid had been mobilized from the cell membrane it is then converted by 





prostaglandins through their respective synthases. PGI2 is one of the most abundant 
prostaglandins, and is produced by prostacyclin synthase (9,30). Once PGI2 is produced it is 
able to stimulate receptors on the VSM cell membrane. PGI2 stimulates the Prostacyclin 
receptor on the VSM membrane, which undergoes a conformational change and activates a 
stimulatory G protein resulting in dilation. (1,31). Figure 2 illustrates the production of PGI2 
and its possible effects on the VSM.  
During endothelial dysfunction, PGI2’s influence on the VSM cell is altered, losing its 
effects as an EDRF and producing VSM responses as an EDCF. The changed role of PGI2 in 
endothelial dysfunction was first noted by Luscher and Vanhoutte in 1986 using SHR (27). 
These investigators noticed impaired dilation during acetylcholine (ACh) dose-responses 
curves, followed by a re-contraction in aortas of SHR compared to WKY controls. The 
dilation was attributed to the effects of NO as normally seen, but the metabolite responsible 
for the re-contraction was unknown. Luscher et al. further examined this re-contraction by 
repeating the ACh dose-response curve in quiescent (non pre-contracted) rings incubated for 
30 minutes with the NOS inhibitor L-NMMA. Under these conditions, ACh stimulation 
results in endothelium-derived contraction that was greatly enhanced in SHR thoracic aorta 
compared to WKY. This contraction could be abolished with the introduction of indomethacin 
(INDO), a non-selective COX inhibitor (9,10,12,32). These experiments indicate that the re-
contraction observed during an ACh dose-response curve can be attributed to COX-mediated 
mechanisms.   Since this initial discovery, much has been done to elucidate the role of PGI2 as 
the main contributor responsible for this re-contraction, and the cellular mechanisms of the 





opposed to relaxation (12). Figure 3 outlines the two types of experiments used by Luscher 
and Vanhoutte to identify the endothelium-derived contractions. 
 Changes in expression of COX in the endothelium and VSM may play a large role in 
the increased EDCFs produced during endothelial dysfunction. Both COX 1 and COX 2 are 
inducible molecules with the ability to become over-expressed in response to stimuli such as 
increased shear stress (33). The endothelium has almost a 20 times greater expression of COX 
than does the VSM, and though both COX 1 and 2 are present, the endothelium preferentially 
expresses COX 1 (4). The SHR CCA also has a much greater expression of COX when 
compared to WKY normotensive controls, indicating an increased COX expression with the 
development of hypertension (12). Another factor of the PGI2 pathway which may lead to an 
increase in EDCF production is prostacyclin synthase, which has been shown to have 
increased expression in SHR. These differences may explain the increase in PGI2 production 
in SHR and the increased magnitude of endothelium-derived contractions exhibited by these 
animals compared to their normotensive controls (WKY) (9,10,32). Similarly to the 
difference in expression of COX seen in the CCA of SHR, the production of EDCF’s between 
COX 1 and 2 sub groups is also not equal. By performing ACh dose-response curves in 
quiescent rings following incubation with selective inhibitors of both COX1 and COX2, it 
was determined that COX1 appears to be the dominant contributor to endothelium-derived 
contractions, while COX2 contributes minimally to the response (34,35).  
 Another important modification that occurs in endothelial dysfunction related to 
EDCF signaling is a change in PGI2 receptor stimulation on the VSM cell membrane. There 
are multiple receptors found on the VSM cell membrane that are affected by the different 





causes relaxation of the VSM as stated above. During conditions of vascular endothelial 
dysfunction there is a loss of the dilatory effect normally observed with PGI2 stimulation. It is 
not clear what causes dysfunction of the prostacyclin receptor leading to a loss of relaxation, 
but it has been shown to occur as early as 3 months of age in SHR (36). It is thought that this 
may be caused by a decrease in expression of the prostacyclin receptor. However, it is still 
unclear if this is the sole cause of prostacyclin receptor dysfunction (36,37).   
 The thromboxane-prostanoid receptor (TP) becomes the main receptor stimulated by 
PGI2 in endothelial dysfunction, resulting in EDCF-mediated contractions. This was 
demonstrated by the blockade of ACh-induced endothelium-dependant contractions using 
thromboxane-prostanoid receptor antagonists in quiescent ring experiments (27). Though the 
thromboxaine-prostanoid receptor can be stimulated by a multitude of COX metabolites 
including thromboxane A2 (TXA2), PGH2 and others, it has been demonstrated by Vanhoutte 
and colleagues that the main contributor to endothelium-dependant contraction during 
endothelial dysfunction is PGI2 (12,30). Figure 4 outlines the dysfunctional roles of PGI2. (38) 
 Both NO and PGI2 play a key role in vasodilation of blood vessels and are contributors 
to the basal tone of the vasculature in a normotensive state. In hypertension, changes in the 
signaling pathways of these molecules are main contributors to endothelial dysfunction (4). 
Reactive oxygen species have also been shown to increase EDCF production by stimulating 
COX and also propagating its signal in the VSM, indicating reactive oxygen species possible 







Reactive Oxygen Species in Endothelial Dysfunction:  
 Hypertension and endothelial dysfunction are associated with an increase in oxidative 
stress in both endothelial and VSM cells (4).  This is mediated by an increase in reactive 
oxygen species including superoxide, hydrogen peroxide, and peroxynitrite(2,4,40). These 
species are produced to some extent in normal physiological conditions, but are increased 
under pathophysiological conditions such as hypertension (4). Increases in reactive oxygen 
species are seen both in patients with essential hypertension and in different animal models 
used to study hypertension such as the SHR (6,41). There are many sources of reactive 
oxygen species in the vasculature which can account for the increased reactive oxygen species 
production. NADPH oxidase, xanthine oxidase, eNOS, and COX 1, and 2, all contribute, but 
NADPH oxidase appears to be the largest contributor of reactive oxygen species in the 
vasculature, producing superoxide anions (2,6). NADPH oxidase is stimulated by angiotensin 
II, a molecule commonly elevated in patients suffering from essential hypertension, which 
leads to an increase in superoxide production and an alteration in the state of oxidative stress 
of the cell (4,42).  NADPH oxidase expression has been shown to increase in hypertensive 
animal models, contributing to the increase in reactive oxygen species (42).  
 It was determined by Kerr and colleagues that the majority of superoxide anions 
produced in the vasculature are endothelium-derived. This was observed in the thoracic aorta 
of SHR and WKY using chemiluminecent dyes, noting there was a significant decrease in 
superoxide production when the endothelium is removed in comparison to the endothelium 
being intact.  SHR aorta had a much larger production than those of WKY (6,43). The 
increase in reactive oxygen species is a main contributor to the development of endothelial 





NO to form peroxynitrite. Both of these molecules are highly unstable and quickly react with 
one another, reducing NO bioavailability, which can account for the impaired dilation 
apparent in endothelial dysfunction. The formation of peroxynitrite not only decreases NO 
bioavailability, but also has a number of destructive consequences due to the instability of this 
molecule. Firstly, peroxynitrite can inhibit SOD, leading to an increase in superoxide anion 
concentration and a decrease in the antioxidant capabilities of the cell (44). Secondly, 
peroxynitrite also inhibits GC which is the downstream target of NO. When sGC is inhibited 
there is a reduction in the vaso-dilatory effect of NO. Resveratrol’s ability to scavenge 
superoxide may reduce peroxynitrite formation and increase NO bioavailability, improving 
NO mediated dilation which is impaired in endothelial dysfunction (45). 
 Superoxide also plays a role in EDCF production, and endothelium-dependant 
contractions of the VSM. It was noted that treatment with antioxidants and antioxidant 
enzymes such as SOD and catalase can reduce endothelium-dependant contractions to ACh in 
quiescent rings of SHR. This indicated that superoxide can play an important role in the 
activation of COX1, leading to the production of EDCF such as PGI2 (41,46). Superoxide’s 
role in the production and propagation of the EDCF signal is shown in figure 4. Reducing the 
increase in reactive oxygen species though scavenging of superoxide could also reduce 
endothelium-dependant contractions, which arise during endothelial dysfunction and 
hypertension. The role of reactive oxygen species in the dysfunctional endothelial signaling 








 Resveratrol, or 3,5,4- trihydroxystilbene, is a naturally occurring polyphenol that can 
be found in a number of plant species including grapes, berries and some nuts and it has been 
shown to confer a number of  health benefits following consumption. Resveratrol exists as 
both cis and trans isomers and though both isomers are associated with health benefits, the 
vast majority of these benefits have been attributed to the more common trans isomer (47). 
Trans resveratrol was most notably known for its proposed role in providing cardiovascular 
protection in the “French Paradox”. The “French Paradox” refers to the French lifestyle which 
incorporates a large number of risk factors for cardiovascular disease, including a high fat 
diet, smoking, minimal physical activity and alcohol consumption. However, as a population, 
the French have one of the lowest rates of cardiovascular disease (48). The low prevalence of 
cardiovascular disease in French society has partially been attributed to the moderate red wine 
consumption of the French population.  Resveratrol, which is found in red wine, has been 
proposed as a molecule responsible for the reduction of cardiovascular disease of the French 
population. Since this proposition numerous research studies have examined the effects of 
resveratrol on the cardiovascular system in both models of health and disease. This research 
has indicated that resveratrol provides a number of benefits for the cardiovascular system, 
some of which act through an endothelium-dependant mechanism. Though research indicates 
resveratrol consumption is associated with a number of benefits, the dosage of resveratrol 
required to provide these benefits is unclear. It is also still yet to be determined if excessive 
consumption can have adverse side effects possibly resulting in toxicity. 
 Resveratrol is readily metabolized by the body, and following oral administration it is 





partially accomplished through the lipophilic properties of resveratrol enabling it to cross the 
plasma membranes of cells. This passive diffusion through cell membranes allows for trans-
epithelial diffusion of resveratrol through the intestinal walls, eventually diffusing into the 
vasculature of the gastrointestinal tract (49,50). Once resveratrol is orally ingested it rapidly 
enters the blood stream reaching its peak plasma concentration within 15 minutes. Though 
resveratrol is readily absorbed by the digestive tract, it has a low bioavailability in plasma due 
to its short half life of 8-14 minutes, its absorption by a number of tissues including the liver, 
kidneys, cardiac and vascular tissue, and  its conversion into a number of metabolites 
including RSV-3-sulfate and RSV-3-O-glucuronide (47,49). The resveratrol concentration in 
the plasma rapidly diminishes after reaching its peak concentration. However, there is a 
second spike in the resveratrol plasma concentration, following the peak plasma 
concentration, indicating there is a small resveratrol storage capacity within the body. This 
storage capacity is a result of resveratrol’s ability to react with hemoglobin and possibly bile, 
being re-released as free resveratrol as the plasma concentration diminishes (49). The peak 
resveratrol plasma concentration was determined in Sprague-Dawley rats by Juan et al. This 
study found that after oral ingestion of 2mg/kg resveratrol the peak plasma concentration 
reaches 586.77 ng/ml 15 minutes following ingestion (51). Similar experiments have also 
shown that the plasma concentrations of resveratrol increase linearly with increasing dosages 
of resveratrol. In addition to this linear relationship it has also been found  that chronic dietary 
treatment with resveratrol over a period of days also leads to an increase in plasma 
concentration (47,49,51). Though these dosages greatly exceed the weight adjusted amount of 
resveratrol consumed by a moderate red wine drinker, there do not appear to be any side 





compound when chronically administered in an excessive dosage of 20mg/kg for a period of 
28 days to Sprague-Dawley rats. This treatment did not result in any changes in growth or 
appearance of the vital organs, and did not alter hematological variables, including red blood 
cell count, hemoglobin measures, white blood cell count and platelet measures. The animal’s 
clinical biochemical markers were also unaltered; these markers include the HDL, LDL, 
triglycerides, blood glucose and a number of metabolite measures. These results indicate that 
resveratrol is safe for chronic dietary treatment at dosages that greatly exceeds normal dietary 
consumption (51).    
 Resveratrol treatment has been shown experimentally to have positive effects in a 
number of disease models associated with free radicals, which includes hypertension (52). 
This is accomplished through resveratrol’s strong antioxidant capabilities, which allows for 
buffering of a number of different reactive oxygen species that can affect endothelial function. 
These reactive oxygen species include hydrogen peroxide; the hydroxyl ion, peroxynitrite and 
the superoxide ion (49).  Resveratrol’s antioxidant scavenging ability is associated with its 
hydroxyl groups which allow for the scavenging of free radicals. Specifically, it is the 4 - 
hydroxystilbene group which enables resveratrol to reduce reactive oxygen species effectively 
(53). Once the hydroxyl group has reduced the free radical, the structure of resveratrol allows 
for the transition of the radical through a number of resonance structures following the 
reaction. These resonance structures enable resveratrol to be stable when reacting with free 
radicals, and give resveratrol its strong antioxidant capabilities. Figure 5 shows the structure 
of resveratrol and highlights the 4 – hydroxystilbene group in the Para position which is a key 





 Though resveratrol has been shown to be a strong antioxidant in-vitro, scavenging 
superoxide, hydrogen peroxide, and the hydroxyl radical, some endogenous antioxidants such 
as superoxide dismutase, catalase and glutathione have been shown to be more potent than 
resveratrol (54). Though resveratrol treatment can play a role in quenching the increase in 
reactive oxygen species that occurs during a disease state like hypertension, through its 
primary antioxidant role, it is likely to have a small impact compared to these more potent 
endogenous antioxidants. Resveratrol has also been shown to be less potent than some other 
exogenous antioxidants such as ascorbate. However resveratrol has been shown to elicit 
effects which can be attributed to more than just its role as a primary antioxidant. These 
additional mechanisms include modulation of endogenous antioxidants, inhibition of some 
pro-oxidant enzymes and also alterations in certain protein expression, all of which have 
beneficial effects to the cardiovascular system (54).  
 Resveratrol has been shown to increase circulating antioxidant activity in plasma; this 
is accomplished by unabsorbed polyphenols acting locally in the gastrointestinal tract. These 
residual polyphenols are able to scavenge free radicals, and prevent lipid peroxidation which 
will in turn spare other antioxidants from oxidation, thus increasing plasma antioxidant 
activity (55). Resveratrol can also mediate benefits that are not related to its antioxidant 
capabilities through its effect on gene regulation of a number of different enzymes and 
proteins, some of which include SOD, catalase, glutathione peroxidase, NADPH oxidase,  
eNOS, and tumor necrosis factor α (56-58). Though the mechanisms by which resveratrol 
influences the expression of these different proteins and enzymes are still not completely 
understood, it has been shown that resveratrol stimulates a number of different transcription 





which are associated with a number of benefits which prolong cellular life span. These 
benefits include modulation of gene expression and mitochondrial function (49). Resveratrol 
is thought to most notably stimulate Sirtuin 1 which in turn stimulates the forkheaded box 
family of transcription factors which controls the expression of a number of proteins, some of 
which become altered in hypertension (49). Resveratrol stimulation of Sirtuin 1 may alleviate 
some of these alterations associated with hypertension. 
 Resveratrol also stimulates the nuclear factor-E2-related factor-2 (Nrf2) transcription 
factor and indirectly, though Nrf2, the antioxidant response element pathway.  This process 
targets numerous reactive oxygen species detoxifying and antioxidant genes. These genes 
include NADPH: quinone oxidoreduxtase and heme-oxygenase-1, and γ-glutamylcystine 
synthase, the rate limiting enzyme for glutathione synthesis (59). Though the pathways by 
which resveratrol regulates gene expression are still not fully characterized it has been 
conclusively shown that resveratrol treatment does alter the protein expression of those listed 
above in a number of studies(56,57,60). Resveratrol treatment has been shown to increase 
SOD, catalase, glutathione, heme-oxygenase-1 and eNOS expression while reducing the 
expression of tumor necrosis factor α and NADPH oxidase. These alterations will have a 
positive effect on relieving the oxidative stress seen during endothelial dysfunction 
(56,57,59). 
 Resveratrol has been shown to reduce oxidative stress through inhibition of pro-
oxidant enzymes including NADPH oxidase and COX. Resveratrol’s down regulation of 
tumor necrosis factor α leads to a decrease stimulation of NADPH oxidase, resulting in a 
reduction in superoxide production (56). Resveratrol has also been shown to inhibit 





superoxide (49). The decreased production of reactive oxygen species, which is accomplished 
through resveratrol’s direct or indirect inhibition of NADPH oxidase, is an important 
contributor to the reduction in oxidative stress seen following resveratrol treatment. The 
combination of resveratrol’s primary antioxidant effects and its secondary effects on the 
modulation of exogenous antioxidants and pro-oxidant enzymes indicate chronic resveratrol 
treatment will improve alterations that are seen during endothelial dysfunction dependent on 
increases in oxidative stress. These effects of resveratrol include improvement of the EDRF 
signaling and reductions of the EDCF signal. Thus resveratrol treatment could lead to positive 
effects on vascular tone and possibly blood pressure in these cases. Non antioxidant effects of 
resveratrol such as alterations in expression of eNOS and COX may also play a role in the 
positive effects of resveratrol (49,61).  
 Results from previous studies conducted in our laboratory using chronic dietary 
resveratrol treatment demonstrated an improvement in NO-mediated dilation. This was 
initially hypothesized to be due to improved NO bioavailability, through an improved 
oxidative state and possibly by an increase in eNOS expression, which has been shown to 
occur in cell culture experiments (61). However resveratrol treatment did not cause an 
increased eNOS expression in either SHR or WKY. This indicates that an improvement in NO 
bioavailability could be mediated through a decrease in reactive oxygen species scavenging of 
NO (52), and also points to a clear possibility that there is a NO-independent component of 
the resveratrol effect. However, this previous chronic resveratrol study had multiple 
limitations. For instance it did not account for possible changes occurring to the EDCF 
pathway following chronic dietary resveratrol treatment (47,49,51,52,57). The study also used 





supplementation. Also the study did not examine the effects of resveratrol treatment on 
endothelium-dependant contractions, PGI2 production, hemodynamic measures, or 
resveratrol-mediated dilation. Furthermore this study also did not use normotensive control 
animals for all experiments. 
 Results from our laboratory have also shown that acute incubation with resveratrol in 
vitro reduces endothelium-dependant contractions and decreases the production of PGI2 
(Jeffery in press). These results indicate that resveratrol has an effect on COX1 function in the 
vasculature which may be mediated through a reduction in reactive oxygen species. Further 
evidence for resveratrol treatment affecting COX1 function is shown through the effect of 
oxidized resveratrol. Resveratrol, when oxidized, has an inhibitory effect on COX function 
(62). The acute  incubation resveratrol study also demonstrated that resveratrol treatment 
leads to an increase in 5' adenosine monophosphate-activated protein kinase phosphorylation, 
a protein capable of relaxation of the VSM and possibly the inhibition of the endothelium-
dependant contractions (63). Thus, previous findings from this laboratory indicate that chronic 
dietary resveratrol treatment may improve endothelial function through a number of 
mechanisms affecting NOS- and COX-mediated signaling.  
Purpose: 
 The following study aims to investigate the effects of chronic dietary resveratrol 
treatment on endothelium-dependant vasomotor function of the CCA as well as on 
hemodynamics of SHR and WKY animals. The study will specifically focus on examining 
1. Resveratrol’s effects on endothelium-dependant vasorelaxations. This will focus on 





dose-dependent effect on endothelium-dependant relaxation, NO sensitivity of the 
VSM and eNOS expression in the CCA.  
2. Resveratrol’s effects on endothelium-dependant contractions. This will focus on 
examining prostacyclin-mediated responses. This will include assessment of 
resveratrol’s dose-dependent effect on endothelium-dependant contraction, PGI2 
production, sensitivity of thromboxane-prostanoid receptor on the VSM, and COX 1 
expression. 
3. Resveratrol’s effects on hemodynamics. This will focus on assessing the dose-
dependent effect of resveratrol on blood flow, conductance and blood pressure.  
 Other secondary experiments examined the effects of chronic dietary 
resveratrol treatment on acute resveratrol-mediated relaxation, 5' adenosine 
monophosphate-activated protein kinase-mediated relaxation, hydrogen peroxide-
mediated contractions and phenylephrine-mediated contractions.  
Hypotheses: 
Hypothesis one: Chronic dietary treatment with resveratrol at a high dose, which mimics a 
resveratrol supplement dose, and at a low dose, which mimics moderate (2 glasses) red wine 
consumption, will improve the relaxation of the SHR CCA to ACh, but have no effect on this 
response in WKY CCA. (Both doses will be weight adjusted to mimic resveratrol doses in 
humans.)  
Hypothesis two: Chronic dietary resveratrol treatment will cause a dose-dependent reduction 
in endothelium-dependant contractions of the CCA VSM in the SHR, but not in the WKY. 





Hypothesis three: Chronic dietary resveratrol treatment will decrease PGI2 production in the 
CCA in a dose-dependent manner in both SHR and WKY. 
Hypothesis four: Chronic dietary resveratrol treatment at a high dose will decrease blood 
pressure and alter blood flow of the SHR but have no effect on the hemodynamics of WKY. 

























Figure1: Both physical and chemical stimuli can activate eNOS acutely through various post 
transcriptional mechanisms, determining the rate of NO production (1). NO that reacts with ROS 
will be reduced to -ONOO and become inactivated (2). Chemicals such as resveratrol and 
antioxidant enzyme systems like SOD,,GPx and Catalase can quench ROS leading to increased NO 













Figure 2: Chemical stimulation of the endothelial cell causes an increase in intracellular 
calcium (1.)This activates PLA2 which mobilizes AA from the cell membrane. AA is converted by 
COX-1 in to endoperoxides (2.) The endoperoxides are then converted into PGI2 and TXA2 which 
















Figure 3: Blood vessels (TA, CCA etc) are dissected and cut to a uniform length and loaded on a 
wire myograph. Vessels equilibrate and are then subjected to one of the following protocols shown. 
EDRF: viability of the vessel is tested using potassium chloride (KCL) which is washed out of the 
tissue bath repeatedly. Once a basal amount of tension is reached the vessel is pre-contracted with 
phenylehprine (PE). Once the force created by the vessel plateaus, an ACh dose response curve 
follows (protocol examines NO mediated dilation). EDCF: viability is tested with KCL and washed, 
once basal tension is reached incubation with L-NMMA follows to inhibit production of NO. 
Following a 30 min incubation period an ACh dose response curve is done (protocol examines 













Figure 4: The mechanisms involved in endothelium derived contractions seen during 
endothelial dysfunction. A stimulus causes an increased intracellular calcium concentration, 
which activates PLA2, releasing arachidonic acid. This is then metabolized by COX1 into 
endoperoxides and then converted in to predominantly PGI2 and, to a lesser extent, TXA2. PGI2 
then causes contraction through stimulation of the TP receptor. ROS are also generated in the 
endothelium and are able to stimulate COX in the VSM, propagating the TP receptor mediated 


















Figure 5: 3,5,4- trihydroxystilbene chemical structure, 4 – hydroxystilbene group in the Para 








 Male Spontaneously Hypertensive Rats (n=35) and male Wistar Kyoto Rats (n=35) 
were purchased from Harlan (Indianapolis,IN) at 13 weeks of age. Rats were group housed in 
a temperature and humidity controlled room and acclimatized to the 12 hour reverse light 
cycle. Rats had free access to standard lab chow (Harlan) and tap water until the age of 16 to 
20 weeks. At this age, the animals were weighed and individually housed in a temperature and 
humidity controlled room with free access to standard lab chow and treated water depending 
on group. The water was changed daily and consumption was monitored.  At 20-24 weeks 
age, following 4 weeks of treatment, animals were weighed and then injected with sodium 
pentobarbital (50-65 mg/kg i.p.; Bimeda-MYC, Cambridge, ON). Level of sedation was 
monitored by measuring the withdrawal from a toe pinch, to ensure proper sedation for 
hemodynamic measures. Following hemodynamic measurements the animals were sacrificed 
by exanguination.  
Resveratrol Treatment: 
 Resveratrol treatment was designed to mimic moderate red wine consumption of 500 
ml/day, and pharmalogical supplementation with resveratrol in a 70 kg human. Moderate red 
wine consumption of 500 ml/day was estimated to be 4.68 mg (64,65). Pharamalogical 
supplementation with resveratrol was estimated to be approximately 500 mg (66).  The 
resveratrol consumption for 500ml/day of red wine was adjusted to a value per kg which was 
0.0668 mg/kg. The per kg value was adjusted to a dosage for a rat, assuming an average rat 





resveratrol. Water consumption per rat was estimated to be 35 ml/day(52), which meant the 
resveratrol concentration must be 0.0006361 mg/ml for the low resveratrol group which 
represents moderate red wine consumption (52). The pharmalogical supplementation group 
was determined to be 100 times the dosage of the low group receiveing 0.06361 mg/ml of 
resveratrol.      
 All animal groups were fed standard laboratory chow and tap water while being 
group-housed. Upon isolation food consumption was recorded over the 4 week period, and the 
drinking water was customized to each experimental group. The control group received tap 
water with 1g/100ml low viscosity carboxymethyl cellulose (MP Biomedicals, Solon OH). 
The low dose resveratrol groups received tap water with 1g/100ml low viscosity 
carboxymethyl cellulose and 0.6361mg/L trans Resveratrol (Toronto Research Chemicals, 
Toronto On). The High dose resveratrol groups received tap water with 1g/100ml low 
viscosity carboxymethyl cellulose and 63.61mg/L trans Resveratrol. Water bottles were 
changed daily and the amount of fluid consumed by each animal was recorded. 
Hemodynamic Measures: 
 Rats were injected with sodium pentobarbital and placed supine on a heating pad 
heated to 38 °C (Gaymar TP-500, Orchard Park, New York and Temp-Pad; Seabrook Medical 
Systems). The left common carotid artery (CCA) was exposed through a small incision in the 
neck and connective tissue was removed. Blood flow through the left CCA was measured 
using a TS240 flowmeter module and a MA1PRB transit-time perivascular flow probe 
(ultrasound frequency, 7.2 MHz; bidirectional flow scale setting, 1V=20ml/min, Transonic 





ml of surgical lubricant, and then the CCA was placed back in to a normal anatomical 
position. A stable blood flow was measured for 5 min after which the probe was removed. 
 Immediately following the measure of blood flow, the CCA was cleaned using a saline 
solution. Blunt ended forceps were used to disrupt flow; once flow has been disrupted a small 
incision was made at the cephalic end of the CCA. A Mikro-Tip pressure catheter (Model 
SPR-320, 2F Mikro-Tip Pressure Transducer Catheter, Millar Instruments, INC., Houston, 
TX) was inserted into the CCA and secured using a removable tie (4-0 surgical suture). Flow 
was restored to the artery and systolic blood pressure, diastolic blood pressure, mean arterial 
blood pressure, and heart rate was measured on a Powerlab console (ADInstuments, Colorado 
Springs, CO) using Chart 5 software (ADInstuments, Colorado Springs, CO, v5.5.4).) 
Vasomotor Assessment:  
 Following the hemodynamic measures the animals were sacrificed via exsanguination. 
The Right CCA was excised, placed in a Krebs-Henseleit buffer (131.5 NaCl, 13.5 NaHCO, 
11.2 glucose, 5.0 KCl, 2.5 CaCl2, 1.2 NaH2PO4, 1.2 MgCl2, and 0.023 EDTA (all in mM)) at 
4 °C, and cleaned using blunt ended forceps.  The CCA was sliced into 2 mm rings using a 
surgical blade under a microscope (Zeiss; VWR, Mississauga, ON) and mounted on a wire 
myograph system (vascular myography unit, Radnoti Glass Technology Inc., Monrovia, CA). 
Two adjacent wires were carefully threaded through the vessel lumen. One wire was attached 
to a force transducer the other was attached to a glass foot. The suspended vessels were placed 
in tissue baths containing 5 ml Krebs buffer at 37°C. Force transduction was measured by 






The rings were slowly adjusted to a basal tension of 2.85 g (previously determined to be 
optimal resting tension for generation of active responses), washing with Krebs buffer every 
10 minutes. Once allowed to equilibrate at 2.85 g, tension viability was tested using 60mM of 
KCl to elicit contraction. After a period of 30 minutes, the rings were washed with Krebs 
buffer 3 times with a spacing of 5 minutes, restoring them to the basal tension in preparation 
for vasomotor function testing. 
Vasorelaxation studies:  
 Rings were pre-contracted with Phenylephrine (PE) (10-6.5 M). Once the contraction 
had reached its plateau, a cumulative dose-response curve was performed using a variety of 
protocols to examine dilatory responses of the CCA to different agonists. The chemicals used 
include ACh, Sodium Nitroprusside (SNP), resveratrol, and 5-aninoimidazole-4-carboxamide-
1-β-Diribofuranoside (AICAR), and indomethacin all of which use different concentrations 
for their respective protocols determined from previous work in the lab. The ACh protocol 
exposed the pre-contracted vessels to increasing concentrations of ACh (10-9 to 10-4M) in a 
cumulative manner. Following the plateau of each concentration of Ach, subsequent 
concentrations were added.  The SNP protocol exposed pre-contracted vessels to increasing 
concentrations of SNP (10-10 to 10-4M) in a cumulative manner. Following the plateau of each 
concentration of SNP, subsequent concentrations were added. For the assessment of NO 
bioavailability the ACh protocol was used following 30 minute incubation with indomethacin, 
this incubation removed the endothelium-dependant contractions and allowed for the 
assessment of NO-mediated relaxation. The resveratrol protocol exposed pre-contracted 
vessels to increasing concentrations of resveratrol (10-6 to 10-4M) in a cumulative manner. 





protocol exposed pre-contracted vessels to three concentration of AICAR (10-7, 10-4, 10-2M) 
in a cumulative manner. Each concentration of AICAR was administered in 30 minute 
intervals.  
Vasocontraction studies:  
 Quiescent rings were incubated with L-NMMA (10-4 M) for 30 minutes before 
addition of any chemicals. Following incubation, an EDCF curve was examined using 
multiple concentrations for each chemical. The chemicals used in the EDCF protocols were 
ACh and H2O2. The ACh protocol exposed the quiescent vessels to increasing concentrations 
of ACh (10-9 to 10-4M) in a cumulative manner. Following the plateau of each concentration 
of Ach, subsequent concentrations were added until maximal contraction was achieved. The 
H2O2 protocol exposed the quiescent vessels to increasing concentrations of H2O2 (10-6 to 10-
3M) in a cumulative manner. Following the plateau of each concentration of H2O2, subsequent 
concentrations were added until maximal contraction was achieved. A cumulative dose-
response curve to phenylephrine was performed in quiescent rings that have not been 




 The buffer from the tissue bath was collected and frozen in liquid nitrogen, and stored 
at -80 °C immediately following peak contraction during the ACh dose-response in quiescent 





of 6-keto-PGF1 in the buffer (stable metabolite of PGI2) using a competitive EIA kit 
according to the manufacturer’s instructions (Cayman Chemical).  These PGI2 values were 
expressed in reference to the length of the CCA ring.  
Vascular Protein Expression:   
 Frozen CCA were hand homogenized in 150μl of ice cold extraction buffer (10mM 
NaH2PO4, 1% SDS, 6M urea at pH 7.4). The homogenates were then incubated at 60 °C for 3 
hours being intermittently vortexed, and then centrifuged (12min, 12000rpm). Following this, 
the Supernatant was removed and frozen at -80°C. The Supernatant was then thawed and a 
bicinchoninic acid protein assay was performed by combining the samples with the BCA 
working reagent (50 parts bicnchoninic acid + 1 part copper II suphate) and compared to a 
bovine serum albumin protein standard. The protein concentration was read on a spectrometer 
(OD 527nm, SpectraMax plus 384, Molecular Devices, Sunnyvale, CA). Following this 
procedure, these samples were prepared for Western blotting by diluting them to 1μg/μl. 
 Prior to electrophoresis (120v for 60-80min) samples were denatured at 95°C for 5 
min and then loaded into the lanes (30μg/lane) of the sodium dodecyl sulphate-
polyacrylamide gels (7.5% SDS-PAGE). The proteins were then transferred onto microporous 
PVDF membranes (25V for 40 min). Immunodetection was performed by first blocking the 
membranes for 1 hour in 5% bovine serum albumin (BSA), then incubating for a specific 
amount of time depending on the primary anti-body (eNOS (1:750):24H, COX1 (1:200):1H). 
This was followed by 1 hour incubation with either horseradish peroxidase-conjugated anti-





horseradish peroxidase/luminol chemiluminescence reagents (Amersham, Little Chalfront, 
UK) and a syngene system (syngene, Cambridge, UK). 
Statistical Analysis: 
 For contraction curves, the tension values were expressed as a percentage of the KCl 
pre-contractions. For relaxation curves, relaxations were expressed as a percentage of 
relaxation from phenylephrine pre-contraction. 
 The pre-contractions and parameters of the dose-response curves were compared using 
2 way ANOVA. The animal characteristics, and hemodynamic measurements, prostacyclin 
production and Western blot results were also compared using a 2 way ANOVA. (α=0.05) 
 Analysis was done using the statistical software SAS for two way and one way 
ANOVAs’, while  curve fitting data including Area under the Curve (AUC) and maximal 














 Food consumption was significantly different between the SHR and WKY strains 
however, there were no differences found in food consumption between the three treatment 
groups within each strain (Table 1). As observed in the previous chronic dietary resveratrol 
treatment study there was a difference in water consumption between the two strains 
(p<0.0001). However, there were no differences found in water consumption between the 
treated groups of each strain (Table 1). Resveratrol consumption of the low and high groups 
successfully reached a level of resveratrol ingestion which represented both moderate red 
wine consumption (SHR=0.0296 mg/day, WKY=0.0216 mg/day) and pharmacological 
supplementation levels (SHR=2.78mg/day, WKY=2.1mg/day) (Table 1). These values, once 
weight adjusted to represent a 70 kg human, represent moderate red wine consumption (6.2 
mg) and pharmacological supplementation (583.8 mg) levels of resveratrol. 
 Similar to previous studies there was a difference in final body weight between the 
two strains. There were no differences observed in the final body weight of the three 
treatment groups of each strain (Table 1). There were also no statistical differences seen in the 
body weight change during the 4 week treatment period with resveratrol in all of the groups. 
(Table 1) 
Hemodynamic Measures: 
 The SHR animals had a significantly reduced mean CCA blood flow in all treatment 





blood flow of (3.8 + 0.36) ml/min whereas the WKY CON had a mean blood flow of (5.0 + 
0.36) ml/min (p=.0254). This finding is consistent with a previous study conducted in our 
laboratory which found SHR blood flow to be reduced (12). In terms of maximal blood flow, 
the SHR CON, LOW, and HIGH groups were significantly reduced compared to their WKY 
counterparts with the exception of the WKY LOW. All groups had similar minimal blood 
flow. Resveratrol treatment had no effect on the blood flow of either strain, with the treated 
groups showing no differences in mean, maximal and minimal blood flow when compared to 
control groups (Table 2).   
 As anticipated, the mean arterial pressure, systolic blood pressure, diastolic blood 
pressure and heart rate of the SHR animals were all significantly greater when compared to 
the WKY animals (P<0.05). Within the SHR strain there was a treatment effect in the SHR 
HIGH group when compared to  the SHR CON group with a reduction in mean arterial 
pressure (P<0.0001), systolic blood pressure (P<0.05), and diastolic blood pressure 
(P<0.0001) . These differences in blood pressure parameters were seen without a significant 
reduction in heart rate of the animals (Table 2). A graphical representation of the changes in 
the mean arterial pressure can be found in figure 6. 
 The mean vascular conductance of the SHR CON was significantly different when 
compared to the WKY CON group (p=0.0001) (Table 2). This finding was similar to previous 
results conducted in this laboratory (12) 
Vasomotor Function: 
 For clarity, the vasomotor function assessment will be reported in two sections. The 





between the strains in the absence of resveratrol treatment. The second section will report the 
results of the comparisons within each strain, examining the differences between the control 
and resveratrol treated groups. 
KCl Contraction  
Comparison between SHR and WKY control group responses 
 There were no differences between the strains in the response to KCl stimulation. The 
SHR CON produced a contraction of (0.99 + 0.027) grams of tension compared to the WKY 
CON which produced a contraction of (0.91 + 0.048) grams of tension. 
Comparison within SHR and WKY treatment groups 
 There were no significant differences in the KCl contraction between the treatment 
groups of each strain.  
Phenylephrine Pre-Contraction  
 Comparison between SHR and WKY control group responses 
 The phenylephrine pre-contractions were significantly different between SHR CON 
and WKY CON. The SHR CON had a reduction in the amount of tension produced with its 
pre-contractions reaching (0.514 + .033) grams of tension after administration of -6.5 Log M   
of phenylephrine. Whereas the WKY CON pre-contractions reached (0.65 + .037) grams of 






Comparison within SHR and WKY treatment groups 
 There were no significant differences in phenylephrine pre-contraction observed 
between the three treatment groups within the WKY strain.  However treatment at a high dose 
of resveratrol appears to increase the contractile response to phenylephrine with the SHR 
HIGH  group reaching pre-contractions of (0.6 + .026) grams of tension compared to the SHR 
CON, which reached (0.514 + .033) grams of tension (p=.044).     
Vasorelaxations: 
 Endothelium-Dependant Vasorelaxations - ACh Dose-Response Curves 
Comparison between SHR and WKY control group responses 
 The SHR CON had a greater maximal relaxation compared to WKY CON (P<.0001) 
in response to ACh at a concentration of 10-4 Log M (Table 3A). This is consistent with 
results previously seen in the literature and indicates the SHR have impaired maximal 
endothelium-dependant vasorelaxations (12).  
 Though this difference in maximal vasorelaxation following a dose of 10-4  Log M 
ACh was seen, there was no difference found between strains following assessment of the 
area under the curve (AUC). (Table 3A) 
 Point-by-point analysis of the ACh dose-response curve reveals that this is because the 
SHR exhibit greater vasorelaxation to smaller concentrations of ACh compared to the WKY 
(Figure 7). To accompany this, the SHR CON group showed impaired vasorelaxations 





indicates that the SHR CON animals exhibit altered endothelium-dependant vasorelaxations 
with impairment of the maximal response to ACh.  
Comparison within SHR and WKY treatment groups 
 As hypothesized there was an increase in endothelium-dependant vasorelaxation 
observed within the treatment groups of the SHR animals. The SHR HIGH showed a greatly 
improved endothelium-dependant vasorelaxation to a maximal dose of ACh compared to SHR 
CON (p<.0001) indicating a treatment effect of resveratrol (Table 3A) (Figure 8). This result 
differs from a previous study performed by our laboratory, which indicated improvement at 
both low and high doses of resveratrol. However differences in the blood vessel used for 
vasomotor assessment may explain these differing results in the vessels` response to ACh.   
 The WKY HIGH, LOW and CON groups exhibited no statistical differences in 
vasorelaxation when compared with eachother with respect to maximal response, point by 
point analysis, and AUC analysis. (Table 3A) (Figure 8)   
Endothelium-Independent Vasorelaxations - Sodium Nitroprusside Dose-Response Curves 
Comparison between SHR and WKY control group responses 
 There were no differences in maximal endothelium-independent vasorelaxations to 
Sodium Nitroprusside between the SHR and WKY control groups. With the SHR CON and 
WKY CON groups demonstrating over 100% endothelium-independent vasorelaxation to a 
maximal dose of Sodium Nitroprusside (Table 3A). Likewise there were no differences 





comparisons of each SNP concentration. These data indicate that there were no differences in 
NO sensitivity or response to NO between the two strains. (Figure 9)  
Comparison within SHR and WKY treatment groups 
 There were no differences in maximal vasorelaxations to Sodium Nitroprusside 
between treatment groups within either SHR or WKY groups. Likewise there were no 
differences found between treatment groups within either SHR or WKY groups with respect 
to AUC and point by point comparisons. Indicating there were no differences in NO 
sensitivity following chronic dietary resveratrol treatment. (Table 3A) (Figure 9)  
Endothelium-Dependant Vasorelaxation With COX 1 and 2 Inhibition - ACh Dose-Response 
Curve Following INDO Incubation 
Comparison between SHR and WKY control group responses 
 Unlike the large difference present in the absence of INDO, there were no differences 
in maximal vasorelaxations to ACh between the SHR and WKY control groups following 
incubation with INDO (Figure 10). Likewise there were no differences observed with respect 
to AUC (Table 3A). Though there was no difference seen between the control groups of each 
strain there was a difference between the entire strains following comparison of AUC. Point-
by-point analysis of control groups illustrated differences between the stains. The SHR CON 







Comparison within SHR and WKY treatment groups 
 There were no significant differences observed in the maximal responses to ACh in 
the presence of INDO between the three treatment groups of the SHR (Figure 9). Likewise 
there were no differences with respect to AUC analysis between the SHR groups. Point by 
point analysis illustrated differences between both SHR HIGH and LOW groups compared to 
the SHR CON. The SHR HIGH group illustrates greater vasorelaxation to multiple 
concentrations of ACh (Figure 10). The SHR LOW group illustrates a reduction in 
vasorelaxations from at a number of concentrations of ACh. The WKY treatment groups 
illustrated no differences in terms of maximal responses, AUC or point by point analysis. 
(Figure 10) 
AICAR Mediated Vasorelaxation   
Comparison between SHR and WKY control group responses 
 The WKY CON group had a greater maximal relaxation to AICAR compared to the 
SHR CON group, but this difference was not statistically significant (Table 3A). Point by 
point analysis indicated a difference between the WKY and SHR responses to AICAR. 
Treatment with 10-4 Log M AICAR the SHR CON group elicited less of a contraction than 
the WKY CON (p=0.0061). (Figure 11) 
Comparison within SHR and WKY treatment groups 
 SHR HIGH and SHR LOW groups have an increased maximal vasorelaxation to 
AICAR compared to the SHR CON group, with the difference between SHR HIGH and CON 





significant difference in response to 10-4 Log M AICAR, with both groups displaying 
vasorelaxation compared to the contraction demonstrated by the SHR CON group. (Figure 11) 
 There were no differences were observed within the WKY treated groups, indicating 
resveratrol has no effect on AICAR mediated dilation in the WKY stain. 
Resveratrol Mediated Vasorelaxation 
Comparison between SHR and WKY control group responses 
 No differences were observed between SHR CON and WKY CON groups with 
respect to vasorelaxation responses to acute resveratrol in vitro (Table 3A) (Figure 12). 
Comparison within SHR and WKY treatment groups 
 The SHR HIGH group displayed greater vasorelaxation throughout the resveratrol 
dose-response curve compared to the SHR CON. This only reached significance at a 
concentration of 10-5 (p=.0199). 
 The WKY HIGH and WKY LOW groups reached a maximal relaxation that was 
much greater than that of the WKY CON group (p<.0001). The WKY HIGH group illustrated 
significantly greater vasorelaxation than the CON group at all concentrations of resveratrol, 
whereas the WKY LOW group had greater relaxations than the CON group only at the high 







 Vasocontractions:  
Endothelium-Dependant Vasocontractions – ACh Dose Response Curve 
Comparison between SHR and WKY control group responses 
 As anticipated there were differences in endothelium-dependant contraction between 
the SHR CON and WKY CON groups. The SHR CON had markedly larger maximal 
contractions when compared to WKY CON (Table 3B). This result confirms the SHR 
dependant increase in endothelium-dependant contractions that has been illustrated in the 
literature (12). To accompany the increase in maximal contraction the SHR CON 
endothelium-dependant contractions are initiated at a lower concentration of ACh when 
compared to the WKY CON (Figure 13). As expected, the SHR CON group displayed a 
greater AUC when compared to the normotensive controls (p=0.0021). These results indicate 
that the SHR have a larger endothelium-dependant contraction response.  
Comparison within SHR and WKY treatment groups 
 High resveratrol treatment reduced the maximal endothelium-dependant contraction of 
the SHR compared to SHR CON (Table 3B). This was accompanied by a significant decrease 
in endothelium-dependant contractions in response to ACh from 10-4.5 to 10-6 Log M in the 
SHR HIGH compare to the SHR CON (Figure 14). This indicates that High resveratrol 
treatment affects endothelium-dependant contractions stimulated by varying concentrations of 
ACh and not just contractions stimulated by a maximal dose of ACh. Though there were 
differences seen in both maximal contractions and point by point analysis, the area under the 





  Though improvements were seen in the SHR HIGH group, the SHR LOW group did 
not have similar reductions in endothelium-dependant contractions as had been hypothesized. 
There were also no differences seen in the response of the treated WKY groups compared to 
the WKY CON. 
Thromboxane-Prostanoid Receptor Sensitivity – U46619 Dose-Response Curve 
Comparison between SHR and WKY control group responses 
 There were no differences found between SHR CON and WKY CON groups in terms 
of maximal contraction, area under the curve and point by point analysis of the U46619 dose-
response curve as shown in table 3B. This indicates that the sensitivity of thromboxane-
prostanoid receptor is unaltered between SHR and WKY animals. 
Comparison within SHR and WKY treatment groups 
 There were no differences found between the resveratrol treatment groups of each 
strain in terms of maximal contraction, area under the curve and point by point analysis of the 
U46619 dose-response curve. These results indicate that chronic dietary resveratrol treatment 
has no effect on sensitivity of the thromboxane-prostanoid receptor. (Figure 15) 
Hydrogen Peroxide 
Comparison between SHR and WKY control group responses 
 There were no differences found between SHR CON and WKY CON in terms of 





response curve (Table 3B). This indicates that H2O2 has a similar effect on both SHR and 
WKY. 
Comparison within SHR and WKY treatment groups 
 There were no differences seen within the SHR groups. This seems to be due to the 
large variability in the responses to hydrogen peroxide as can be seen in figure 14. There were 
differences seen in the WKY groups with the WKY HIGH having greater contractions at a 
number of concentrations of H2O2 compare to WKY CON (Figure16). Unlike the WKY 
HIGH group, there were no differences between the WKY LOW and the WKY CON groups. 
Phenylephrine Dose-Response Curve 
Comparison between SHR and WKY control group responses 
 The maximal contraction to PE is reduced in the SHR CON compared to the WKY 
CON (p=0.0238) (Table 3B), confirming previous results from this laboratory (12). The 
reduced contractions to PE stimulation were observed at multiple concentrations throughout 
the dose-response (Figure 17). Though there were multiple differences seen in the point by 
point analysis there was no difference in the AUC between the two strains. 
Comparison within SHR and WKY treatment groups 
 Chronic dietary resveratrol treatment at a high dose increased the maximal response to 
PE in the SHR. The SHR HIGH groups had an increased maximal contraction to PE 
compared to the SHR CON (p<0.0001). This indicated that the maximal response to PE was 





SHR HIGH group had increased contraction to PE at a number of different concentrations 
(Figure 17). Though there were differences seen at a number of different concentrations of PE 
in the SHR the AUC data was not significantly different. 
 There were no differences between the WKY groups in terms of maximal response, 
point by point analysis, and area under the curve analysis. These results indicate that 
resveratrol treatment does not affect the response of the WKY animals to PE. 
Biochemical analysis: 
6 keto PGF 1α Competitive EIA Assay – Prostacyclin Production 
 As expected there was an increase in the prostacyclin production in the SHR CON 
group compared to the WKY CON group. This increase in production in the SHRs CCA 
coincides with results from previously shown in this laboratory in both the CCA and the 
thoracic aorta (Jeffery in press) (67).  
 Treatment with resveratrol at a high dose blunted the SHR-dependant increase in 
prostacyclin production; however the resveratrol treatment at a lower dose had no effect. The 
SHR HIGH group prostacyclin production was 189 + 30 pg/ml compared to the SHR CON 
production of 519 + 93 pg/ml. This reduction in SHR HIGH prostacyclin production resulted 
in a similar production as the WKY CON and corresponded with a reduction in endothelium-







Vascular protein expression: 
Western Blotting - COX 1 Protein Expression 
 As previously characterized in the literature (38,68) and shown by this laboratory in 
previous studies (12) the SHR CON had a greater COX 1 protein content when compared to 
WKY CON, which expressed 1.9 + 0.26 and 1  + 0.10 (arbitrary normalized units) (p=0.834) 
respectively. Though this difference is not a significant difference, there is an SHR dependant 
increase in COX 1 protein content. There were no differences seen between the resveratrol 
treated groups of either strain (Figure 19). 
Western Blotting - eNOS Expression        
 The eNOS protein content of the SHR CON was elevated compared to WKY CON as 
had been shown in the CCA previously (12). The SHR CON expressed eNOS at a level 3.11 
+ 0.6 compared to the WKY CON 1 + 0.3 (arbitrary normalized units) (p=.05). There were no 
differences seen in eNOS protein expression in response to treatment with resveratrol in either 
















Table 1: Animal and Consumption Parameters 
Strain WKY                        SHR  
Resveratrol Group CON LOW HIGH CON LOW HIGH 
Water Consumption (ml)δ 37+1†  35+0.85† 34+0.85† 45+1.8† 48+2.2† 45+1.9†  
Resveratrol Consumption 
(mg) 
0 0.021 2.1 0 0.030 2.78 
Food Consumption (g) δ 487.4+11†  491.6+8 500.6+10† 542.95+12† 519.7+6.3 550.2+11† 
Final Body Weight (g) δ 312.8+10 313.6+5.2 321.44+4.5 345.5+5 329.4+2.8 343.2+11 
Body Weight Change (g) 22.7+7 14.7+5.5 17.9+4.2 19.2+4.6 20.8+2 12+5.2 
       











Table 1: Physical and consumption parameters: δ represents differences between strains, † represents 









Table 2: Hemodynamic Parameters 
Strain WKY SHR  
Resveratrol Group CON LOW HIGH CON LOW HIGH 
Heart rate# 264+13† 257+15† 260+11† 382+ 13† 375+ 14† 359+14† 
CCA Blood Flow, 
ml/min 
      
Maximum δ  19.0+1.7  15.5+1.9 22.0+1.7† 11.6+1.7   9.8+1.7  11.4+1.7†  
Minimum  1.90+0.58 1.58+0.63 1.88+0.58 0.62+0.58 0.87+0.58 -0.26+0.58 
Mean δ 5.0+0.36†  4.4 +0.365 5.5+0.36† 3.8+0.36†  3.4+0.36  2.9+0.36†  
CCA Blood Pressure, 
mmHg 
      
Systolic δ 89+4† 93+4† 91+3† 215+4† 207+4† 173+4†θ 
Diastolic δ 67+4† 72+5† 69+4† 162+4† 157+5† 131+5†θ 




      







Table 2: Hemodynamic parameters: δ represents differences between strains, † represents differences 
within treatment group, and θ represents differences within strain compared to control group. Values 








Table 3A: Vasomotor Assessment Parameters 
Drug Condition  WKY                         SHR 
CON LOW HIGH CON LOW HIGH 







86.2+6%† 92.8+5%† 90.5+4% 53.6+6%† 50.2+9%† 99.4+5%θ 






































































112.1+8% 114.9+6% 118.4+7% 94.5+6% 112.6+2%θ 116.3+5%θ 
AUC 
 









Table 3A: Vasomotor assessment parameters: Response to a maximal dose (MR) expressed as a 
percent relaxation from pre-contraction and area under the curve (AUC) of vasorelaxation 
assessment. δ represents differences between strains, † represents differences within treatment 
group, and θ represents differences with strain compared to control group. Values are mean + 







Table 3B: Vasomotor assessment parameters 
Drug Condition  WKY                             SHR 
CON LOW HIGH CON LOW HIGH 







30+6%† 27+7%† 25+6%† 68+5%† 66+5%† 55+5%†θ 
















































34+12% 18+6%† 52+13% 33+6% 49+13%† 43+12% 














Table 3B: Vasomotor assessment parameters: Response to a maximal dose (MR) expressed as 
a percent of KCl contraction and area under the curve (AUC) of vasocontraction assessments. 
δ represents differences between strains, † represents differences within treatment group, and 
θ represents differences with strain compared to control group. Values are mean + s.e.m.: 

















Figure 6: mean arterial blood pressure: Significant differences were seen between 
the CON of SHR and WKY. Differences were also seen between SHR HIGH and 








Figure 7: Endothelium-dependant vasorelaxation to ACh expressed as a percent relaxation 
from PE-precontraction. SHR Con compared to WKY Con, N=8 per group , significant  
differences seen between SHR High and Con groups. Values are means + s.e.m.: significance 






































































































































































Figure 9: Endothelium-independent vasorelaxation to Sodium Nitroprusside expressed 
as a percent relaxation from PE precontraction. NO differences seen between groups. 










































































































































































































































































































































































































































































































Figure 13: Endothelium-dependant contactions to ACh in quiescent rings of the CCA 
following L NAME incubation expressed as a percent KCl contraction. SHR Con compared 
to WKY Con, N=8, Significant differences were seen between the SHR CON and HIGH 
























































































































































































Figure 15: Endothelium-independent contractions to TP receptor agonist U46619 
in quiescent rings of the CCA expressed as a percent KCl contraction. N =5. 



















































































































































































Figure 17: Contraction to Phenylephrine in quiescent rings of the CCA expressed 
as a percent of KCl contraction. N=5.Significant differences seen in the SHR CON 
contractions compared to SHR HIGH. Values are means + s.e.m.: significance 



















Figure 18: Prostacyclin production in CCA rings stimulated with ACh. N=7. † 
represents differences within treatment group, and θ represents differences within strain 
















Figure 19: Protein values of COX 1 normalized to WKY CON group.  N= 4 per group. 















Figure 20: Protein values of eNOS normalized to WKY CON group, N= 4 per group. † 








 The purpose of this study was to investigate the effects of chronic dietary resveratrol 
treatment on endothelium-dependant control of vasomotor function in the CCA, and to 
elucidate the differences in hypertensive and normotensive animal models. The main findings 
of this study are: 
1. Resveratrol treatment at a high dose improves endothelium-dependant vasorelaxation 
to ACh in the SHR; however a low dose of resveratrol does not have the same effect. 
2. Resveratrol treatment at a high dose reduces the endothelium-dependant contraction to 
ACh in the SHR; however a low dose of resveratrol does not have the same effect. 
3. Resveratrol treatment at a high dose reduces PGI2 production of the CCA of the SHR. 
Treatment at a low dose causes only a small reduction in the SHR PGI2 production. 
4. Resveratrol treatment had no effect on the sensitivity of the thromboxane-prostanoid 
receptor in the SHR or WKY. 
5. SHR exhibit markedly increased blood pressure and an altered blood flow profile 
compared to WKY. Resveratrol treatment at a high dose reduces the blood pressure of 
the SHR, but does not affect the blood flow profile. 
6. Resveratrol treatment also had minor effects on AICAR mediated relaxation, 









 The SHR control group had a greater average final body weight of 33 grams when 
compared to the WKY (p=0.0556) however, this difference was not significant. The lack of 
significance between these two control groups could possibly be due to the large age range at 
which the animals were sacrificed ranging from 21 weeks and 3 days to 24 weeks of age. 
However, there was a difference in final body weight following comparison of the entire 
stains, this coincides with previous studies conducted by this laboratory which have 
conclusively shown an increase in body weight in the SHR when compared to the 
WKY(12,32).  
 Resveratrol treatment had no effect on the final body weight of either strain which is 
supported by the previous chronic dietary resveratrol treatment study conducted by Rush et al. 
(52). Table 1 illustrates that both the SHR and WKY groups follow a similar trend, indicating 
that resveratrol treatment had no effect on the final body weight of the animals. 
 There was a significant difference between strains in the total amount of food 
consumed throughout the 4 week treatment period (Table 1).  There were no differences seen 
in the amount of food consumption between the control groups and the resveratrol treated 
groups of the respective strains indicating that resveratrol did not have an effect on the 
appetite of the animals.   
 As had been demonstrated in previous chronic dietary resveratrol studies, there were 
significant differences in the daily water consumption of the animals with the SHR consuming 





consumed similar amounts of treated water as the control groups indicating that the 
resveratrol treatment did not affect the amount of water consumed by the animals.  
 Consistent water consumption in the resveratrol treated groups in comparison to 
control groups allowed for resveratrol treatment to achieve levels that were calculated in the 
methods section (Table 1). These dosages of resveratrol were then weight adjusted to a weight 
of 70 kg. Assuming 0.333 kg  for the average rat, the low group would have received 6.2 mg 
following weight adjustment to 70 kg, which is a level of resveratrol consumption in the 
realm of moderate red wine consumption (64,65).  The high group would have received 583.8 
mg of resveratrol following weight adjustment to 70 kg. This 583.8 mg dosage is equivalent 
to pharmacological resveratrol supplementation currently available (66).  
 Due to the difference in water consumption between the two strains, SHR and WKY 
animals will have received slightly different levels of resveratrol during the treatment (Table 
1).  
Endothelium-Dependant Vasorelaxation: 
 SHR display impaired endothelium-mediated vasorelaxation to ACh in phenylephrine 
pre-contracted vessels (4). Vessels from the SHR have a robust relaxation to small 
concentrations of ACh but this relaxation is abolished by a re-contraction with the 
administration of higher concentrations. The re-contraction of the CCA has been 
demonstrated to occur due to alterations in both NO and PGI2 signaling from the endothelium 
in the SHR but not the WKY (2,4,5,12). The impaired endothelium dependant vasorelaxation 
in the CCA has been confirmed by the current study with the SHR control group 





 Resveratrol treatment at both a low and high dosage was hypothesized to reverse the 
reduction in endothelium-dependant vasorelaxations through actions on the NO pathway. 
However, unlike the previous chronic dietary resveratrol treatment study conducted by Rush 
et al., treatment at a low dose of resveratrol did not provide improvements in the response to 
ACh (52), (Table 3A) (Figure 8). This result indicates that treatment with a low dose of 
resveratrol does not affect the impaired relaxation seen in the CCA. The discrepancy between 
the previous chronic dietary resveratrol study conducted by Rush et al. and the present study 
may be due to the use of a different blood vessel. Though both are conduit arteries, the 
thoracic aorta used by Rush et al. may have been more susceptible to resveratrol treatment 
than the CCA used in the present study (52). The Rush et al. study also used fewer 
concentrations of ACh during the endothelium-dependant relaxation experiments and was 
unable to reproduce the re-contraction in SHR at higher dosages of ACh. This re-contraction 
during ACh dose-response curve in SHR has been established in the literature and was able to 
be reproduced in the current study (4).  
 Resveratrol treatment at a high dose illustrated improvements in the ACh mediated 
relaxations with the SHR high group, reaching a relaxation of almost 100% following a 
maximal dose of ACh (Table 3A). The resveratrol treatment provided the SHR high group 
with a similar relaxation to the normotensive WKY (Figure 8). This improvement in 
endothelium-dependant relaxation may have been partially caused by a number of alterations 
throughout the NO signaling pathway, including improved VSM’s sensitivity to NO, 
increased NO bioavailability through decreased NO scavenging, and an increase in NO 





 Results from the current study using Sodium Nitroprusside, a NO donor, illustrated 
that there were no differences in the VSM sensitivity to NO between SHR and WKY 
following resveratrol treatment (Figure 9). This finding is supported by the previous work by 
Rush et al. indicating that the SHR had no alteration in the relaxation to Sodium Nitroprusside 
following chronic dietary resveratrol treatment (52). These results indicate that treatment with 
resveratrol has no effect on the NO sensitivity of the VSM which means that the 
improvements in endothelium-dependant relaxations, which occurred following resveratrol 
treatment, cannot be attributed to changes in the VSM sensitivity to NO and must have 
resulted from other alterations in the NO pathway.  
 ACh mediated relaxation following COX inhibition with indomethacin was used to 
functionally assess the alteration in NO bioavailability. The SHR high group has increased 
relaxations throughout the ACh dose-response curve; however this only reached significance 
at two concentrations. Low resveratrol treatment appeared to have the opposite effect on NO 
bioavailability compared to the high resveratrol treatment, resulting in reduced relaxations 
throughout the ACh dose-response curve (Figure 10). This result points to low resveratrol 
treatment reducing NO bioavailability or having a complex interaction with the PGI2 pathway 
in an ACH-dose-dependent manner. This is perplexing considering the previous findings 
which illustrate low resveratrol treatment to have a positive effect on endothelium-mediated 
relaxation (52). A low bioavailability of resveratrol at the CCA could explain the lack of 
improvements in endothelium-dependant relaxation observed in the SHR low group when 
compared to the SHR high group. Though the current and previous resveratrol study 
conducted by the Rush laboratory are the first to our knowledge to use multiple dosages of 





vasomotor response, a number of in vitro studies have illustrated a concentration dependency 
on resveratrol effects (61,69). The dose dependency of resveratrol’s effects may explain why 
the SHR low group does not show an improvement in the functional measure of NO 
production.  The current study’s improvements in NO bioavailability in the SHR high group 
could be attributed to alterations in NO production and NO scavenging. 
 As anticipated, the SHR exhibit an increased eNOS expression in comparison to the 
WKY (Figure 20). This increased eNOS expression in the SHR has been shown in numerous 
studies (2,12). However, this increased expression is not necessarily associated with an 
increase in NO production as was shown by Bhatt et al., who have shown that eNOS 
uncoupling can result in a decrease production of NO (70). Resveratrol treatment had no 
effect on the expression of eNOS in either SHR or WKY. This result was surprising due to the 
fact that a number of cell culture experiments have linked resveratrol treatment to increased 
eNOS expression (61).  Though the previous chronic dietary resveratrol study also did not 
show increase in eNOS expression, the alteration in the resveratrol dosage used for the present 
study was hypothesized to have an effect on eNOS expression. Recent studies from other 
laboratories have shown increases in eNOS expression using resveratrol dosages of 
5mg/kg/day and above (70-72), however, studies using red wine polyphenols did not show 
this increase in eNOS expression (73).  Despite the recent evidence that resveratrol can 
increase eNOS expression in vivo this study was unable to replicate these results. Alterations 
in NO signaling pathway, which have provided improvements in the endothelium-dependant 
relaxations, must be attributed to other alterations and not an increase in eNOS expression. 





 The improvements in endothelium-dependant relaxation can be partially attributed to 
alterations in NO signaling. Recent studies have shown that resveratrol treatment has a 
number of effects on the NO pathway which could lead to the increased NO bioavailability 
demonstrated by the current study. Both Rush et al. and Bhatt et al. have shown that 
resveratrol treatment alters the oxidative state of the endothelial cells in the vasculature 
showing a decrease in reactive oxygen species production (52,70). This reduction in reactive 
oxygen species leads to a decreased production of peroxynitrite, which in turn leads to an 
increased NO bioavailability. This is supported by Bhatt et al. who showed an increased 
production of NO in the SHR following resveratrol treatment. Resveratrol’s improvements in 
NO-mediated relaxation appear to be partially mediated by a reduction in NO scavenging by 
reactive oxygen species.  
 Bhatt et al. have demonstrated that NO production in SHR is actually smaller than 
WKY, even though there is a greater expression of eNOS in the SHR animals (70). This 
decreased NO production is attributed to eNOS uncoupling, which decreases eNOS’s ability 
to produce NO and instead leads to the production of superoxide. This is caused by a decrease 
in the necessary co-factors needed for eNOS to convert L-Arginine to NO. One of these co-
factors is tetrahydrobiopterin which is essential for stabilization of the eNOS dimer and 
greatly affects its affinity for L-Arginine. Tetrahydrobiopterin is sensitive to the increase in 
reactive oxygen species that is seen during hypertension and this leads to a decrease in 
tetrahydrobiopterin. Reduction in tetrahydrobiopterin in turn results in an increase in eNOS 
uncoupling leading to a decreased production of NO and an increased production of 
superoxide (74). Chronic dietary resveratrol treatment has recently been shown by Bhatt et al. 





superoxide produced by eNOS and increased NO production (70). An increase in NO 
production via this mechanism could be the key contributor to improved NO-mediated 
relaxation to ACh observed in SHR of the current study following chronic dietary resveratrol 
treatment. 
 Alterations in endothelium-dependant contractions can also contribute to the 
improvements observed in endothelium-dependant relaxations. Figure 10 shows that 
following COX inhibition there is a remarkable improvement in the endothelium-dependant 
relaxation to ACh when compared to the result without COX inhibition in figure 7. 
Endothelium-Dependant Vasocontraction: 
 As expected, the response to ACh in quiescent CCA rings following incubation with 
L-NMMA were much greater in the SHR controls when compared to the WKY controls 
(Figure 13). This increase in endothelium-dependent contractions is a hallmark of endothelial 
dysfunction caused by an alteration in the PGI2 signaling pathway, which has been 
documented in the literature to be the main contributor to endothelium-dependant contractions 
(4,9,10,68,75,76) (12,32). The difference in endothelium-dependant contractions between 
SHR and WKY has been replicated by multiple studies and confirms that the SHR used in the 
present study do suffer from endothelial dysfunction (4,12,27,32,38,68,75).  
 As opposed to the hypothesis that resveratrol would reduce endothelium-dependant 
contraction at both dosages, only the SHR high resveratrol group exhibited a reduction in the 
endothelium-dependant contractions. The SHR low group produced similar contractions as 
the SHR control group (Table 3B), this result is consistent with the lack of improvement in 





high group displayed a reduction in the endothelium-dependant contractions (Figure 14), 
indicating that resveratrol treatment has an effect on the PGI2 pathway.  
 The results from the current study expand upon previous, unpublished findings from 
an acute  incubation resveratrol treatment study conducted in this laboratory, which 
demonstrated diminished endothelium-dependant contraction in the SHR (Jeffery in press), 
and now demonstrated similar findings in a chronic dietary treatment model. Previous 
research by Kane et al. has illustrated that chronic dietary treatment using wine polyphenols at 
150mg/kg/day produced a reduction in endothelium-dependant contractions in an Angiotensin 
II rodent model of hypertension, which supports the current findings (77).  
 While the reduction in endothelium-dependant contractions is able to partially explain 
the improvements seen in the endothelium-dependant relaxations it is evident that the 
reduction cannot fully explain the improved endothelium-dependant relaxations, indicating 
that the NO component discussed earlier had a partial role in improved relaxation (Figure 
8,14). The reduction in the endothelium-dependant contraction could be caused by a number 
of alterations in the PGI2 pathway which include an alteration in VSM PGI2 sensitivity, a 
decrease in PGI2 production which could be caused by an alteration in arachidonic acid 
production, COX activity, COX expression or prostacyclin synthase expression all of which 
will be discussed. 
 The thromboxane-prostanoid receptor is the receptor stimulated by PGI2 during the 
signaling cascade of endothelium-dependant contractions (68). This receptor produces 
contraction of the VSM and when selectively inhibited, abolishes the endothelium-dependant 





was not different between the SHR and WKY CCA following treatment with resveratrol 
(Figure 15). This result indicates that the reduced endothelium-dependant contractions 
following resveratrol treatment are not mediated through an alteration in the thromboxane-
prostanoid receptor sensitivity (Figure 15) (Table 3 B). Interestingly, the thromboxane-
prostanoid receptor sensitivity to U46619 and other agonists has been reported to be different 
between WKY and SHR, the SHR exhibiting hypersensitivity to thromboxane-prostanoid 
receptor agonists. However, these results were seen in the thoracic aorta and not in the CCA, 
which may help to explain the discrepancy (38).  
 As expected, PGI2 production was significantly increased in the SHR control group 
compared to the WKY (Figure 18). This SHR dependant increase in PGI2 production has been 
documented throughout the literature and is thought to be a key contributor to the increase in 
endothelium-dependant contractions and progression of endothelial dysfunction (68). 
Resveratrol treatment produced a reduction in the SHR dependant increase in PGI2 
production. The SHR high group illustrated the greatest reduction in the PGI2 production as 
can be seen in figure 18 with production levels reaching those similar to the WKY control 
group. The SHR low group demonstrated a reduction in PGI2 production but this was not 
significantly different compared to the SHR control group, and did not result in a decrease in 
endothelium-dependant contractions (Figure 14). The reduction in PGI2 production could 
have been mediated through a reduction in arachidonic acid, an inhibition of COX 1, a 
reduction in the COX 1 expression or possibly a reduction in prostacyclin synthase 
expression. Resveratrol has been shown to inhibit PGI2 production as was shown in the 
previous acute incubation resveratrol study (Jeffery in press) and documented in the literature 





endothelium-dependant vasomotor function that are seen following chronic dietary resveratrol 
treatment.    
 As expected there was an increase in COX 1 expression in the SHR control group 
when compared to the WKY control group. Though this increase was not significant it is 
supported by results from previous studies showing an SHR dependant increase in COX 1 
expression (11,12,75). This increase in COX 1 expression is likely to contribute to the SHR 
increase in PGI2 production and the increase in endothelium-dependant contraction seen in the 
progression of hypertension. Following resveratrol treatment there is a slight reduction in 
SHR COX 1 expression but this change is not significant (Figure 19). The reduction in COX 
1 that was demonstrated in the current study may contribute to the reduced PGI2 production; 
however this reduced PGI2 production also appears to be mediated to a greater extent by the 
inhibition of COX 1by resveratrol or possibly through a decrease in arachidonic acid 
production resulting in a reduction in PGI2 production. 
 The reduction in endothelium-dependant contraction produced by chronic dietary 
resveratrol treatment plays a key role in the improvement of the endothelium’s control of 
vascular tone. Resveratrol’s affect on endothelium-dependant contractions appears to be 
mediated through alterations in the production and signaling pathway of PGI2. Inhibition of 
PGI2 production through COX inhibition eliminates endothelium-dependant contractions 
similar to acute incubation resveratrol treatment and to a degree, chronic dietary resveratrol 
treatment (9,12) (Jeffery in press). Evidence that the reduction in endothelium-dependant 
contractions is mediated through a reduction in PGI2 is provided by the lack of effect of 





  A reduction in the PGI2 signal is the most likely alteration to provide the reduction in 
endothelium-dependant contractions in the current chronic resveratrol study. Support for the 
reduction in PGI2 production being the key contributor to the blunted contractions seen in the 
current study comes from multiple sources in the literature. Kane et al. studied the effect of 
wine polyphenol treatment in the angiotensin II model of hypertension; these researchers 
demonstrated a reduction in blood pressure and also a reduction in the endothelium-dependant 
contractions angiotensin II model (77). Though Kane et al. did not measure PGI2 production 
directly, it was reported that following treatment with wine polyphenols there was a 
significant reduction in COX 1 and COX 2 expression which was attributed to an improved 
oxidative state provided by the red wine polyphenols. COX expression had been demonstrated 
to be unregulated by an increase in reactive oxygen species, a reduction in reactive oxygen 
species production or increase in scavenging could reduce COX expression (78). The 
reduction in COX 1 and 2 expressions demonstrated by Kane et al. was associated with a 
reduction in endothelium-dependant contractions and was likely caused by a reduction in 
PGI2 production (77). 
 Though the current study did not demonstrate a significant reduction in COX 1 
expression (Figure 19) a reduction in PGI2 production was still noted. Resveratrol could have 
been able to produce reduced PGI2 production through inhibition of COX 1, a reduction in 
arachidonic acid production, mediated through an alteration in phospholipase A2 activity, or a 
reduction in prostacyclin synthase expression. Resveratrol has been shown to inhibit COX 1 
activity in a dose-dependent manner in vitro (79). Resveratrol’s ability to reduce oxidant 
content in the cell can reduce the activity of COX 1 (49,62,80). The reduced activity is 





The inhibition is a result of the lack of oxidation of an iron catalytic subunit in the COX 
molecule which results in a lack of production of PGH2 (49,81). Resveratrol’s effect on 
phospholipase A2 and prostacyclin synthase has yet to be detailed in the literature and could 
be partially responsible for the reduction in PGI2 production exhibited in the present study.   
  
 The reduction in PGI2 production is the key contributor to the reduced endothelium-
dependant contractions, and this has been mediated through either resveratrol’s inhibitory 
effect on COX 1 or also possibly through a reduction in arachidonic acid through actions 
possibly effecting phospholipase A2. The inhibitory effect on COX 1 is due to resveratrol’s 
antioxidant capabilities within the cell decreasing the presence of reactive oxygen species, 
(49,52,56,57,59,60,70,82,83).      
Hemodynamic Measures: 
 The mean, maximum and minimum CCA blood flow values in the SHR were all 
reduced compared to the normotensive WKY, indicating impairment in the hemodynamic 
measures of the SHR hypertensive model (Table 2). This finding was similar to previous 
results from Denniss et al. which found both decreased blood flow and conductance in to 
CCA of the SHR when compared to WKY (12). The altered hemodynamics measure in the 
SHR is also supported by the reduction in CCA blood flow in human patients with essential 
hypertension (84). The current study further established the impairment in CCA blood flow 
seen in models of essential hypertension and examined the effects of chronic dietary 
resveratrol treatment on this measure. Following chronic dietary treatment with resveratrol 
there were no alterations in the CCA blood flow in either strain (Table 2), indicating that 





knowledge this is the first study to assess the CCA blood flow of a hypertensive model 
following resveratrol treatment so no literature is available to support the finding that 
resveratrol treatment does not have an effect on CCA blood flow. 
 The MAP of the SHR control group was 176 + 6 mmHg compared to the WKY 
control groups MAP of 78 + 7 mmHg indicating that the SHR had a marked increase in blood 
pressure which is congruent with results from the literature (12,52). This result indicates that 
the SHR do suffer from hypertension and endothelial dysfunction that is associated with this 
increase in blood pressure. 
 The current study found that, following 4 weeks of treatment with resveratrol at a high 
dose of 2.7 mg/kg/day, the blood pressure was reduced in comparison to age matched SHR 
(Table 2). This reduction in blood pressure is likely due to improvements of the endothelium-
dependant vasomotor function altering the vascular tone of the hypertensive animals.  A 
recent study has shown similar effects of resveratrol treatment of a much greater dose of 
10mg/kg/day for 8 weeks in obese Zucker rats causing a reduction in blood pressure (71). A 
study by Diebolt et al. illustrated a reduction in blood pressure following treatment with wine 
polyphenols and attributed the reduced blood pressure to the polyphenols effects on NO 
signaling (45). Kane et al. demonstrated a reduction in blood pressure in the angiotensin II 
model following treatment with red wine polyphenols, the reduction in blood pressure 
illustrated by this study was attributed to a reduction in endothelium-dependent contractions 
that was deomostrated during vascular assessment (77). The current study attributes 
resveratrol’s reduction in the SHR blood pressure to both improvements in NO signaling and 






 A number of studies have been conducted using chronic resveratrol application which 
have shown improvements in endothelial function, however no alterations in blood pressure 
were found in these studies (52,85). However, these studies used varying dosages and 
treatment periods, whereas the studies listed above and a recent study conducted by Bhatt et 
al. used a resveratrol or wine polyphenol treatment in excess of 5 mg/kg/day. The Bhatt et al. 
study which used a similar resveratrol dosage to the current study found a similar reduction in 
blood pressure in the SHR (70). Bhatt et al. attributed this reduction to improvements in 
endothelial function similar to the results of the current study (70).  
AICAR and Resveratrol-Mediated Relaxation: 
 SHR and WKY control group responses to AICAR differed throughout the dose-
response curve. Following administration of AICAR at a -4 Log M the WKY control group 
showed a slight contraction which was 30% greater than the phenylephrine pre-contraction. 
Whereas the SHR control group showed almost no contraction following this dose of AICAR 
(Figure11).  
 Resveratrol treatment at both a low and high dose resulted in greater relaxations 
throughout the AICAR dose-response curve in the SHR (Figure 11). This increase in 
relaxation could possibly be caused by an increase in 5' adenosine monophosphate-activated 
protein kinase phosporylation. In a previous acute incubation resveratrol study it was found 
that resveratrol increases 5' adenosine monophosphate-activated protein kinase 
phosphorylation (Jeffery in press). The increase 5' adenosine monophosphate-activated 
protein kinase phosphorylation can lead to an increased eNOS stimulation and production of 





dysfunction expression and activation of 5' adenosine monophosphate-activated protein 
kinase are reduced, which may contribute to impaired NO-mediated signaling (63,86). 
Resveratrol treatment has been shown to salvage the 5' adenosine monophosphate-activated 
protein kinase expression and activation in some models of endothelial dysfunction (86). It is 
possible that the resveratrol treatment has had a similar effect in the SHR of the present study 
leading to an increase in NO production and in turn an increase in relaxation.  
 Resveratrol, along with its numerous antioxidant and gene expression effects, has been 
shown to cause relaxation of pre-contracted vessels in both endothelium-dependant and 
independent manners (Jeffery in press) (87,88).  This process has been shown to be partially 
mediated through the NO signaling pathway, demonstrated by the partial inhibition of 
resveratrol mediated relaxation following incubation with L-NMMA (87,89). Resveratrol has 
had an effect on the NO mediated component of the endothelium-dependant vasorelaxation of 
the SHR, however the resveratrol mediated relaxation in the SHR appears to be unaffected by 
the resveratrol treatment. All three of the SHR groups reached similar levels of maximal 
relaxation and no differences were seen in the area under the curve analysis (Table 3A). The 
only difference occurred at a concentration of -5 Log M with the high resveratrol group 
showing slightly increased relaxation. Interestingly the WKY animals resveratrol mediated 
relaxation was greatly affected by resveratrol treatment.  The resveratrol treatment led to an 
increase in maximal relaxation and an alteration in the resveratrol dose-response curve that 
can be seen in (figure 12). This novel finding merits further investigation into the mechanisms 
behind the increase in resveratrol mediated relaxations to determine if this alteration is 
endothelium-dependant or independent, working through the NO signaling pathway or 






 Phenylephrine contractions have been shown to be reduced in the SHR when 
compared to WKY (12).  This alteration is thought to be caused by an alteration in the α-1- 
adrenoreceptor subtypes in the SHR, which have been shown to be altered as early as 12 
weeks of age (90).In this study the SHR control group demonstrated a reduction in the 
response to phenylephrine stimulation in comparison to the WKY control group, which is 
characteristic of the alterations seen in the α-1- adrenoreceptor. The reduced response to 
phenylephrine is illustrated in figure 17 and table 3B. Resveratrol treatment restores the 
response to phenylephrine, producing similar contraction to the WKY control group (Table 3 
B) (Figure 17). This is possibly accomplished by altering the expression of the α-1- 
adrenoreceptor subtypes to one that is similar to the WKY (90). Chronic dietary resveratrol 
treatment had no effect on the response of the WKY to phenylephrine. Further research into 
the possible alterations that are occurring to the α-1- adrenoreceptor subtypes during 
resveratrol treatment should be conducted to elucidate the mechanisms involved. 
Limitations:  
 Though resveratrol supplementation in the drinking water of the animals is a common 
method used in the research field, this method has its limitations (52,70,77). Firstly resveratrol 
treatment through drinking water supplementation is not as precise as other methods such as 
an intraperitoneal injection with resveratrol. Resveratrol treatment using water 
supplementation assumes that the water that is removed from the bottle is consumed by the 
animal which does not take into account residual dripping and other factors such as 





done ad libitum, which can cause a discrepancy in the amount of resveratrol removed from 
the water bottles either through consumption or manipulation by the animals. This 
discrepancy was demonstrated in the present study by the different amounts of resveratrol 
received by the SHR and WKY groups. Given the alternative of daily intraperitoneal 
injections which has its own limitations including stressing the animal we chose to use water 
supplementation. Though there were limitations to the resveratrol treatment of this study it is 
apparent from the results that the treatment did have an effect, indicating that the treatment 
was successful. 
 This study was limited in its ability to assess the tissues uptake of resveratrol. The 
inability to monitor the free resveratrol concentration in the vasculature limits the capability 
of this study to attribute the results to either acute effects of resveratrol following recent 
ingestion or chronic effects of resveratrol treatment. However the resveratrol concentration 
that is found in the blood plasma following dietary treatment at a similar dose to the present 
studies high dose is minimal, reaching 600 ng/ml of plasma (51). The small plasma 
concentration of resveratrol reduces the chance that the results seen in this study were due to 
acute ingestion effects and more likely to be a result of the chronic effects of dietary 
resveratrol treatment. To further support that the results from the present study can be 
attributed to the chronic effects of resveratrol, the time elapsed from when the animals are 
sedated for hemodynamic measurement to the actual assessment of vasomotor function is 
much greater than the half life of resveratrol in the body. This supports the conclusion the 
results from this study are due to the chronic effects of resveratrol and not acute effects of 





 This study was limited by the method in which hemodynamic measures were taken. 
Blood pressure and blood flow measurements were preformed while under anesthesia. Taking 
hemodynamic measures under anesthesia has been criticized due to the fact that under 
anesthesia heart rate and blood pressure values can be reduced.   However, the hemodynamic 
results from the present study match trends in anesthetized animals from previous studies and 
these results were similar to those recorded in conscious SHR using noninvasive methods 
such as the tail cuff method (12,91). 
 This study was also limited in its ability to directly assess NO production, with 
methods previously used by this laboratory lacking the sensitivity to measure differences in 
NO production. Functional assessments were used in an attempt to measure differences in the 
NO production; however this method is not a direct measure of NO production. Firstly, the 
differences in relaxation may not fully represent differences in NO production. Secondly, 
inhibiting COX 1 and 2 may decrease the production of reactive oxygen species altering the 
effects on NO bioavailability. The relaxation occurring may not be able to be attributed to just 
NO. Other endothelium-derived relaxation factors may also play a role such as hydrogen 
sulfide and hydrogen peroxide, though these appear to have a greater role in the resistance 
arteries rather than conduit arteries (92,93). Though this is not a direct measure of NO 
production it provides a good functional assessment of NO contribution to endothelium-
dependant relaxation.    
 Finally, biochemical analysis was limited by the amount of viable tissue available. 
Tissue used in vasomotor assessment could not be used due to stimulation from chemical 





removal of the endothelium. Not being able to use tissue from vasomotor or hemodynamic 
assessment limited the amount of viable tissue available for western blotting analysis.         
Conclusion: 
 This study demonstrated that chronic dietary resveratrol treatment improves the 
endothelial function of SHR in the CCA, though not as originally hypothesized. Treatment at 
a low dose of resveratrol which mimics red wine consumption did not have as marked an 
effect as previous studies, providing no improvements in endothelium-dependant relaxation 
and endothelium-dependant contractions (52). Treatment at a high dose of resveratrol, which 
mimicked pharmacological supplementation, demonstrated a number of changes in 
endothelial function. This treatment alleviated dysfunction seen in endothelium-dependant 
relaxations, reduced endothelium-dependant contractions, which lead to a reduction in blood 
pressure of SHR. This was achieved through a number a possible effects of resveratrol 
treatment. Resveratrol’s effect on NO signaling is possibly mediated through a reduction in 
reactive oxygen species reducing NO scavenging by superoxide. This reduction was shown in 
previous studies (52,70). Resveratrol’s ability to increase in SOD activity may have 
contributed to this as was shown by Bhatt et al. (52,65,70). A reduction in eNOS uncoupling 
also could have improved NO bioavailability.  
 Reduced endothelium-dependant contractions that were observed following high 
resveratrol treatment were mediated by a reduction in PGI2 production, which was 
accomplished by the inhibition of COX 1. This is supported by the lack of change in the 
sensitivity of the thromboxaine prostanoid receptor, and the reduction in PGI2 production 





 Although this study was limited in identifying the exact mechanisms by which 
resveratrol altered both NO and PGI2 signaling, it is evident that resveratrol treatment acting 
through these pathways was able to improve endothelium-dependant control of vascular 
smooth muscle in a model of hypertension associated with endothelial dysfunction. This 
makes resveratrol treatment an interesting option for further research as a possible treatment 
in humans.               
Future directions: 
 This study has provided significant evidence for resveratrol’s effect on endothelium-
dependant control of vasomotor function. Experiments which could further develop the 
understanding of resveratrol’s effect on endothelium-dependant vasomotor function in the 
present study include western blot analysis of phospholipase A2 expression in the CCA, as 
well as measurement of arachidonic acid production. This analysis would further elucidate 
resveratrol’s effect on PGI2 production and thus endothelium-dependant contractions.  Future 
studies should focus on the biochemical changes that are occurring during chronic dietary 
resveratrol treatment which allow for these improvements. These include assessment of 
reactive oxygen species production, pro oxidant and anti oxidant enzymes, and other proteins 
integral in the endothelial control of vascular tone. Assessment of the effect of resveratrol on 
the contractile proteins in the VSM is another area which needs to be elucidated. Assessment 
in the alterations of α-1- adrenoreceptor subtypes which were illustrated by the current study 
must also be assessed in future studies to fully understand resveratrol’s effect on these 
receptors. Finally, the results that have been shown in models of essential hypertension like 
the SHR must be replicated in humans to solidify resveratrol’s treatment effects on 
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